Castle Biosciences (NASDAQ:CSTL – Get Free Report) will likely be posting its Q3 2025 results after the market closes on Monday, November 3rd. Analysts expect Castle Biosciences to post earnings of ($0.35) per share and revenue of $71.0620 million for the quarter. Castle Biosciences has set its FY 2025 guidance at EPS.Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Monday, November 3, 2025 at 4:30 PM ET. Get ...

核心观点 - 市场预计Castle Biosciences公司2025年第三季度业绩将出现同比下滑，每股亏损预期为0.34美元，营收预期为7130万美元 [1][3] - 实际业绩与市场预期的对比是影响股价短期走势的关键因素 [1][2] - 尽管公司拥有Zacks Rank 1的评级，但由于其盈利意外预判指标为0%，难以确定其能否超出每股收益预期 [12][13] - 相比之下，同行业的Biogen公司因盈利意外预判指标为+0.86%且Zacks Rank为3，更有可能超出每股收益预期 [20][21] 公司业绩预期 - 预计季度每股亏损为0.34美元，同比变化为-525% [3] - 预计季度营收为7130万美元，同比下降16.9% [3] - 过去30天内，季度每股收益共识预期保持不变 [4] 盈利意外预测模型 - Zacks盈利意外预判指标通过比较“最精确预期”与“共识预期”来预测实际业绩偏离程度 [7][8] - 该模型对于正向的盈利意外预判指标有显著的预测能力 [9] - 当正向盈利意外预判指标与Zacks Rank 1、2或3结合时，预测股价上涨的准确性较高 [10] 公司历史表现与当前预测 - 上一报告季度，公司实际每股收益为0.15美元，超出亏损0.51美元的预期，意外幅度达+129.41% [14] - 在过去四个季度中，公司有三次超出每股收益预期 [15] - 公司当前的盈利意外预判指标为0%，Zacks Rank为1 [12] 行业对比 - 同行业公司Biogen预计季度每股收益为3.89美元，同比下降4.7% [19][20] - Biogen预计季度营收为23.4亿美元，同比下降5.1% [20] - Biogen的每股收益共识预期在过去30天内下调了2.7%，但其盈利意外预判指标为+0.86% [20] - Biogen的Zacks Rank为3，结合其盈利意外预判指标，显示其很可能超出每股收益预期 [21]

FRIENDSWOOD, Texas, Oct. 26, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating that its TissueCypher® Barrett’s Esophagus test can provide risk insights beyond pathology alone, influencing clinical management to support earlier intervention for those at higher risk of progression to esophageal cancer and potentially reducing unnecessary procedures for those at lower risk. The r ...

This new histological subtype data confirms DecisionDx-Melanoma’s clinical value across the spectrum of melanoma Castle Biosciences will also present validation data on its atopic dermatitis pipeline test FRIENDSWOOD, Texas, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it is presenting data on its DecisionDx®-Melanoma test and its pipeline atopic dermatitis (AD) gene expression pro ...

Castle Biosciences, Inc. (CSTL) closed the last trading session at $23.74, gaining 4.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $35.63 indicates a 50.1% upside potential.The average comprises eight short-term price targets ranging from a low of $30.00 to a high of $41.00, with a standard deviation of $3.54. While the lowest estimate indicates an increase of 26.4% from the c ...

Castle Biosciences, Inc. (CSTL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the sy ...

财务信息发布日期 - 公司将于2025年11月3日美股市场收盘后公布2025年第三季度及前九个月的财务业绩 [1] 业绩发布活动安排 - 公司管理层将于2025年11月3日美东时间下午4:30举行电话会议和网络直播讨论财务业绩 [1] - 电话会议接入号码为美国1 833 470 1428，接入码为735311，国际拨入号码可通过特定链接获取 [3] - 网络直播可通过投资者关系页面或特定链接访问，建议提前至少10分钟接入 [2] - 管理层评论后将设有简短的问答环节 [3] 公司业务概览 - 公司是一家领先的诊断公司，通过创新的测试指导患者护理以改善健康 [4] - 公司当前产品组合包括针对皮肤癌、Barrett食管和葡萄膜黑色素瘤的测试 [5] - 公司拥有活跃的研发项目，针对中重度特应性皮炎患者的全身治疗选择指导测试正在开发中 [5]

公司核心事件 - Castle Biosciences公司创始人、总裁兼首席执行官Derek Maetzold被《CEO Magazine》评为2025年度首席执行官 [3] - 该奖项旨在表彰那些驱动可衡量影响力、创新和鼓舞人心的资深高管 [3] - Maetzold从586名申请人中脱颖而出，最初被选为仅有的10名决赛入围者之一，最终获奖 [1][5] 领导力与公司成就 - 在Maetzold的领导下，公司从一家初创企业成长为领先的诊断公司 [4] - 其领导力将科学创新与以人为本的方法相结合，对患者护理和公司发展产生了显著影响 [4] - 公司培养了以人为本的文化，连续四年被员工反馈评为美国顶级工作场所 [4] 业务与产品组合 - Castle Biosciences是一家领先的诊断公司，通过创新测试指导患者护理以改善健康 [6] - 公司当前产品组合包括针对皮肤癌、Barrett食管和葡萄膜黑色素瘤的专有测试 [4][7] - 公司拥有活跃的研发项目，针对上述疾病及其他高临床需求的领域进行测试开发，包括一款用于指导中重度特应性皮炎患者选择生物制剂系统疗法的在研测试 [7] - 公司拥有包括DecisionDx-Melanoma、TissueCypher等在内的多个注册商标 [8]

FRIENDSWOOD, Texas, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been recognized as a Greater Pittsburgh Top Workplace by The Pittsburgh Post-Gazette. The designation is based exclusively on anonymous employee feedback gathered through a third-party survey. The confidential survey measures several aspects of workplace culture designed to be indicative of employee satisfacti ...

公司荣誉与认可 - 公司入选《新闻周刊》首届2025年美国最伟大公司榜单 排名涵盖650家美国企业[1] - 评选基于财务实力、员工敬业度、创新以及环境可持续性和企业道德承诺四大关键支柱[1] - 公司致力于"以人为本"的理念 涵盖患者诊疗、创新文化构建及业务全方位发展[2] 业务与产品组合 - 公司为领先诊断企业 通过创新检测技术改善患者健康管理[3] - 当前产品组合包括皮肤癌、巴雷特食管和葡萄膜黑色素瘤检测试剂[4] - 研发管线涵盖中重度特应性皮炎患者生物制剂系统治疗选择指导检测等项目[4] 核心技术资产 - 拥有DecisionDx-Melanoma、DecisionDx-UM、TissueCypher等10项注册商标[5] - 评估数据来源包括美国证券交易委员会文件、专利商标局记录及第三方数据源[2]